Globus strengthens position as UK's leading force in hand protection

Published: 5-Mar-2010
Personal Protection Regulatory

Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.

Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.

From 1 March 2010 Globus has taken over all Showabest activities in the UK and Ireland. The addition of unique chemical protection products and the world's most advanced disposable glove offer gives Globus the only product portfolio that can claim the original iconic styles that created totally new markets for their distribution partners.

Grip style gloves, Palm Fit technology, Dyneema cut protective gloves and the world's first and patented disposable nitrile glove were all created by the Showabest organisation.

Innovative sales & marketing techniques have seen Globus rise to the forefront of the hand protection sector. Its customers now look set to enjoy the benefits of an invigorated range supported by UK stock and extensive sales support infrastructure.
See more

You may also like

Regulatory

BIOSECURE Act on track to curb Chinese biotech investment in the US

Read more
The amended Act was included in the annual defence bill after failing to pass muster in the last key defence spending bill, but has some notable omissions

Trending Articles

  1. UK-US pharma deal removes tariffs and boosts access to innovative medicines The UK has secured a zero-tariff agreement on pharmaceutical exports to the US, alongside major reforms to accelerate NHS access to new treatments
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Revolutionising temperature control: the benefits of thermal insulated coatings in the pharmaceutical industry Insulation is safety critical in pharmaceutical factories, where hot pipes and equipment pose a significant burn risk to workers. Yet traditional approaches often fall short in terms of durability and longevity … and can be expensive to install and maintain
  3. Ardena strengthens executive leadership with key quality and IT appointments Appointments reflect focus on quality, compliance, and digital integration across global network
  4. Piramal Pharma Solutions’ bioconjugates facility in Grangemouth, UK, receives updated MHRA GMP certificates These certificates cover all activities conducted in the site’s Helix building, including its supporting warehouse and laboratory areas
  5. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Regulatory

BIOSECURE Act on track to curb Chinese biotech investment in the US

The amended Act was included in the annual defence bill after failing to pass muster in the last key defence spending bill, but has some notable omissions
Regulatory

One in four European pharma companies at risk of regulatory breaches according to NSF research

The independent survey exposed significant gaps in quality systems, supply chain oversight and data integration, just as EU GMP regulations continue to tighten
Personal Protection

Vileda Professional CE launches revolutionary single-use microfibre mopping system

Vileda Professional CE launches revolutionary single-use microfibre mopping system for cleanrooms and controlled environments
Manufacturing

Autopack launches modular semi-automatic bucket line

Flexible system helps manufacturers improve efficiency and reduce costs
Regulatory

NICE raises cost-effectiveness thresholds to boost UK pharma innovation

The UK government has confirmed that NICE will increase its cost-effectiveness thresholds to £25,000-£35,000 per QALY from April 2026, with the aim to support pharmaceutical companies and unlock patient access to new medicines
Manufacturing

A-Z Color advances automated quality control in pharmaceutical label production

EyeC inspection systems help deliver zero-error labels and GMP-compliant reliability
Personal Protection

DuPont and Empa collaborate to advance comfort in protective clothing

Independent tests prove the exceptional breathability of DuPont’s next-generation protective garments
Subscribe now